Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Rituximab, and Ibrutinib Strategy in Treatment-Naïve CLL
NCT04758975Phase 2Recruiting
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, rituximab and ibrutinib in chronic lymphocytic leukemia (CLL). Primary endpoint: Undetectable Minimal Residual Disease at 27 months. Started Sep 2022; status: recruiting.
02
Drugs
venetoclaxrituximabibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04758975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758975.